p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?

Poller, David; Baxter, K J; Shepherd, N A

doi:10.1038/bjc.1997.14

Cited by 63 publications

(28 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We detected 55.7% (39 of 70) of IHC-positive cases when the cutoff value for p53 positivity was set at 5%. The frequency of the positive p53 staining observed was consistent with reported data, ranging from 44.8 to 60.8% (Bosari et al 1994;Poller et al, 1997). In this study, association between p53 protein nucleic overexpression and p53 gene mutation was obtained for 28 patients (71.8%).…”

Section: Discussionsupporting

confidence: 79%

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

Lopez-Crapez

Bibeau²,

Thézenas³

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

The aim of this study was to evaluate, in a prospective study, the predictive role of p53 status analysed at four different levels in identifying the response to preoperative radiotherapy in rectal adenocarcinoma. Before treatment, 70 patients were staged and endoscopic forceps biopsies from the tumour area were taken. p53 status was assessed by total cDNA sequencing, allelic loss analysis, immunohistochemistry, and p53 antibodies. Neoadjuvant treatment was based on preoperative radiotherapy or radiochemotherapy. Response to therapy was evaluated after surgery by both pathologic downstaging and histologic tumour regression grade. In all, 35 patients (50.0%) had p53 gene mutations; 44.4% of patients had an allelic loss; nuclear p53 overexpression was observed in 39 patients (55.7%); and p53 antibodies were detected in 11 patients (16.7%). In the multilevel analysis of p53 status, gene mutations correlated with both nuclear protein overexpression (Po0.0001) and loss of heterozygosity (P ¼ 0.013). In all, 29 patients (41.4%) were downstaged by pathologic analysis, and 19 patients (29.2%) were classified as tumour regression grade 1. Whatever the method of evaluation of treatment response, no correlation between p53 alterations and response to radiotherapy was observed. Our results do not support the use of p53 alterations alone as a predictive marker for response to radiotherapy in rectal carcinoma.

show abstract

Section: Discussionsupporting

confidence: 79%

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

Lopez-Crapez

Bibeau²,

Thézenas³

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…There are two major studies investigating the prognostic significance of pRb in colorectal cancer (Poller et al, 1997;Cui et al, 2004). In the first study (Poller et al, 1997), pRb immunohistochemical expression was evaluated in 250 primary resectable colorectal carcinomas.…”

Section: Gastrointestinal Cancermentioning

confidence: 99%

“…In the first study (Poller et al, 1997), pRb immunohistochemical expression was evaluated in 250 primary resectable colorectal carcinomas. Positive nuclear Rb1 staining was observed in 82.8% of cases examined and did not correlate with patient age, sex, site of tumor, tumor size, tumor type (standard or mucinous adenocarcinoma), tumor grade, peritumoral lymphocytic infiltrate, nature of the invasive tumor margin, extramural vascular or lymphatic invasion, lymph node involvement, involvement of peritoneum and Dukes' stage.…”

Section: Gastrointestinal Cancermentioning

confidence: 99%

RB family members as predictive and prognostic factors in human cancer

2006

View full text Add to dashboard Cite

mentioning

confidence: 97%

“…Overexpression of the p53 protein is detectable in 30-70% of the tumours using immunohistochemistry. In some studies (Remvikos et al, 1992; Sun et al, 1992;Auvinen et al, 1994;Bosari et al, 1994) p53 protein overexpression has been shown to correlate to patient survival, while this has not been confirmed in other studies (Bell et al, 1993; Baas et al, 1994;Dix et al, 1994a;Morrin et al, 1994;Mulder et al, 1995;Kressner et al, 1996Poller et al, 1997).Mutant p53 protein, and other tumour-specific antigens, may be a target of the host's immune response (Schlichtholtz et al, 1992;Mudenda et al, 1994). Studies have shown that 9-26% of patients with different carcinomas have mounted a humoral immune response (antibodies) to abnormal p53 protein (Caron de Fromental et al, 1987;Levine et al, 1991;Angelopoulou et al, 1994).…”

mentioning

confidence: 99%

Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer

Kressner

Glimelius²,

Bergström³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Serum p53 antibody levels were analysed using an enzyme-linked immunosorbent assay in serum samples obtained before surgery from 184 consecutive patients with primary colorectal cancer. Possible associations with tumour stage and tumour differentiation and the relation to patient survival time after a median follow-up of 6 years were studied. Analysis of serum p53 antibodies in the entire material demonstrated prognostic value in univariate analysis (P = 0.02); a finding that did not remain (P = 0.07) when the Dukes' stage was included in a multivariate analysis model. When the survival analysis was restricted to the potentially cured patients in Dukes' stages A-C, the serum p53 antibody levels retained independent prognostic value (P = 0.03). No clear association with tumour differentiation was found. We conclude that analysis of serum p53 antibodies may be of value for the identification of patients with different prognoses. This may be of relevance for selection of patients for adjuvant treatment.Keywords: serum p53 antibody; colorectal cancer; tumour stage; tumour differentiation; survival; immunohistochemistry Mutations or other changes in the p53 gene -the most frequent genetic alterations found in human malignancies (Levine et al, 1991;Harris and Hollstein, 1993) -can be detected in 40-70% of all colorectal adenocarcinomas (Hollstein et al, 1991; Vogelstein and Kinzler, 1992;Hamelin et al, 1994;Chang et al, 1995). It has been reported that p53 mutations are associated with poor prognosis in colorectal cancer (Hamelin et al, 1994;Goh et al, 1995;Finkelstein et al, 1996; al, 1997), while such a relation was not observed by Dix et al (1994a). Overexpression of the p53 protein is detectable in 30-70% of the tumours using immunohistochemistry. In some studies (Remvikos et al, 1992; Sun et al, 1992;Auvinen et al, 1994;Bosari et al, 1994) p53 protein overexpression has been shown to correlate to patient survival, while this has not been confirmed in other studies (Bell et al, 1993; Baas et al, 1994;Dix et al, 1994a;Morrin et al, 1994;Mulder et al, 1995;Kressner et al, 1996Poller et al, 1997).Mutant p53 protein, and other tumour-specific antigens, may be a target of the host's immune response (Schlichtholtz et al, 1992;Mudenda et al, 1994). Studies have shown that 9-26% of patients with different carcinomas have mounted a humoral immune response (antibodies) to abnormal p53 protein (Caron de Fromental et al, 1987;Levine et al, 1991;Angelopoulou et al, 1994). Thus, anti-p53 antibodies may be a serological marker for malignancy.Recent studies have shown increased serum antibody levels against mutant p53 protein in patients with breast (Crawford et al, 1982;Davidoff et al, 1992;Schlichtholtz et al, 1992;Mudenda et al, 1994), lung (Winter et al, 1992;Schlichtholtz et al, 1994) and Immunohistochemical analysis of overexpression of p53 protein p53 protein overexpression was evaluated using an immunohistochemical method (Kressner et al, 1996). Briefly, DO-7 monoclonal antibody was used in combination with ...

show abstract

p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?

Cited by 63 publications

References 34 publications

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

RB family members as predictive and prognostic factors in human cancer

Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer

Contact Info

Product

Resources

About